KLOW (GHK-Cu / KPV / BPC-157 / TB-500)
Muscle/RecoveryRegenerative blendExperimental
Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.
For research use only.
Key Facts
- CAS
- โ
- Molecular Weight (MW)
- Varies
- Half-life
- Varies
- Unit
- mg
- Administration Route
- Subcutaneous
- Frequency
- Daily
- Last updated
- 8/23/2026
- Targets
- Multiple (component-dependent)
Overview
Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.
Protocol
- Dosage Range
- 1-2 mg total
- Frequency
- Daily
- Cycle
- 4-6 weeks on, 4 off
- Administration Route
- Subcutaneous
- Reconstitution Guide
- 5 mL BAC for 80 mg blend
Science
Mechanism of Action
Intended multi-pathway blend (repair, angiogenesis, copper-peptide matrix, ฮฑ-MSH anti-inflammatory fragment). No registration trial of KLOW as a product.
Targets
Multiple (component-dependent)
Studies
- BPC-157 reviewโ Journal/year not available
Benefits
Tissue repairInflammation reductionSkin rejuvenationRecovery
Potential Side Effects
- Irritation
- Nausea
References
- WADA Prohibited List 2026External link ยท Year โ